This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Case Report
Richard M Fleming, PhD, MD, JD
FHHI-OI-Camelot
Corresponding Author
ORCiD: https://orcid.org/0000-0001-9964-1518
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Declarations:
Declarations
- This study involved human subjects.
- The author confirmed that all appropriate ethical guidelines for the use of human subjects have been followed, any necessary IRB and/or ethics committee review has been obtained, and information about the IRB/ethics committee is included in the manuscript.
- The author has confirmed that all necessary patient/participant consent or assent has been obtained and the appropriate institutional forms have been archived. If the IRB/ethics committee waived the requirement for patient/participant consent or assent, an explanation for the waiver is included in the text.
- This study reports on a clinical trial.
- The author has confirmed that this trial has been registered with an ICMJE-approved registry, and the trial registration ID has been provided in the text. If the article reports on a study that was registered retrospectively, a statement explaining why the study was not registered in advance has been provided in the text.
- This study is a case report.
- The author has confirmed that consent for publication of clinical details and/or clinical images was obtained from the patient/parent/guardian/relative of the patient or waiver of such consent is described in the text.
- The author has confirmed that a statement listing potential conflicts of interest or lack thereof is included in the text.
Currently there is no established treatment protocol for SARS-2 (CoVid-19). Proponents of hydroxychloroquine (HCQ) argue that early intervention may sufficiently prevent replication of the virus and avoid the need for hospitalization. In instances where viral replication continues and the patient develops CoViD pneumonia (CVP), such patients – particularly with comorbidities – are prone to develop an InflammoThrombotic response similar to cytokine release syndrome (CRS). We present one such patient who failed HCQ treatment and was subsequently treated successfully with an interleukin-6 inhibitor and interferon.
Keywords
SARS-CoV-2, CoVid-19, FMTVDM, Ferritin, IL-6, NCT04349410
Figure 1
This is a list of supplementary files associated with this preprint. Click to download.
- IRBConsentForm.pdf
Redacted IFC
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 30 Oct, 2020
Community comments: 7
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Case Report
Richard M Fleming, PhD, MD, JD
FHHI-OI-Camelot
Corresponding Author
ORCiD: https://orcid.org/0000-0001-9964-1518
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 30 Oct, 2020
Community comments: 7
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Declarations:
Declarations
- This study involved human subjects.
- The author confirmed that all appropriate ethical guidelines for the use of human subjects have been followed, any necessary IRB and/or ethics committee review has been obtained, and information about the IRB/ethics committee is included in the manuscript.
- The author has confirmed that all necessary patient/participant consent or assent has been obtained and the appropriate institutional forms have been archived. If the IRB/ethics committee waived the requirement for patient/participant consent or assent, an explanation for the waiver is included in the text.
- This study reports on a clinical trial.
- The author has confirmed that this trial has been registered with an ICMJE-approved registry, and the trial registration ID has been provided in the text. If the article reports on a study that was registered retrospectively, a statement explaining why the study was not registered in advance has been provided in the text.
- This study is a case report.
- The author has confirmed that consent for publication of clinical details and/or clinical images was obtained from the patient/parent/guardian/relative of the patient or waiver of such consent is described in the text.
- The author has confirmed that a statement listing potential conflicts of interest or lack thereof is included in the text.
Currently there is no established treatment protocol for SARS-2 (CoVid-19). Proponents of hydroxychloroquine (HCQ) argue that early intervention may sufficiently prevent replication of the virus and avoid the need for hospitalization. In instances where viral replication continues and the patient develops CoViD pneumonia (CVP), such patients – particularly with comorbidities – are prone to develop an InflammoThrombotic response similar to cytokine release syndrome (CRS). We present one such patient who failed HCQ treatment and was subsequently treated successfully with an interleukin-6 inhibitor and interferon.
Figure 1
This is a list of supplementary files associated with this preprint. Click to download.
- IRBConsentForm.pdf
Redacted IFC
Loading...